Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020;29(2):49-53.
doi: 10.1297/cpe.29.49. Epub 2020 Apr 16.

Ultra-low-dose estrogen therapy for female hypogonadism

Yukihiro Hasegawa  1 , Tomoyo Itonaga  1   2 , Kento Ikegawa  1 , Satsuki Nishigaki  3 , Masanobu Kawai  4 , Eri Koga  5 , Hideya Sakakibara  5 , Judith L Ross  6
Affiliations
Review

Ultra-low-dose estrogen therapy for female hypogonadism

Yukihiro Hasegawa et al. Clin Pediatr Endocrinol. 2020.

Erratum in

Abstract

In females, endogenous estrogen secretion increases gradually before pubertal development. The benefits of low-dose estrogen therapy in patients with Turner syndrome were originally discussed by Ross et al. and Quigley et al. These seminal studies used ethinyl estradiol (EE2), starting at a dose of 25 ng/kg/d. We hypothesized that the initial dosage of estrogen could be titrated to more closely mimic physiological increments of endogenous estrogen. Therefore, our recent study initiated EE2 treatment at a dosage of 1-2 ng/kg/d, an ultra-low-dose estrogen therapy in pediatric patients with Turner syndrome. The ultra-low-dose estrogen therapy in this syndrome produced a good final height outcome but achieved suboptimal bone mineral density (BMD). In the present review, we have explained our findings to clarify the merits and demerits of this new therapy and to promote further discussion and research. This type of ultra-low-dose estrogen therapy, initiated at an early age, could be ideal for estrogen replacement in female patients with hypogonadism, such as Turner syndrome.

Keywords: Turner syndrome; estrogen therapy; hypogonadism; ultra-low-dose.

PubMed Disclaimer

References

    1. Ross JL, Quigley CA, Cao D, Feuillan P, Kowal K, Chipman JJ, et al. Growth hormone plus childhood low-dose estrogen in Turner’s syndrome. N Engl J Med 2011;364: 1230–42. doi: 10.1056/NEJMoa1005669 - DOI - PMC - PubMed
    1. Quigley CA, Wan X, Garg S, Kowal K, Cutler GB, Jr, Ross JL. Effects of low-dose estrogen replacement during childhood on pubertal development and gonadotropin concentrations in patients with Turner syndrome: results of a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 2014;99: E1754–64. doi: 10.1210/jc.2013-4518 - DOI - PMC - PubMed
    1. Hasegawa Y, Ariyasu D, Izawa M, Igaki-Miyamoto J, Fukuma M, Hatano M, et al. Gradually increasing ethinyl estradiol for Turner syndrome may produce good final height but not ideal BMD. Endocr J 2017;64: 221–7. doi: 10.1507/endocrj.EJ16-0170 - DOI - PubMed
    1. Suwa S, Tachibana K. Standard growth charts for height and weight of Japanese children from birth to 17 years based on a cross-sectional survey of national data. Clin Pedtric Endocrinol 1993;2: 87–97. doi: 10.1297/cpe.2.87 - DOI
    1. Gravholt CH, Andersen NH, Conway GS, Dekkers OM, Geffner ME, Klein KO, et al. International Turner Syndrome Consensus Group. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol 2017;177: G1–70. doi: 10.1530/EJE-17-0430 - DOI - PubMed